Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025807 | 0.85 | CACNA2D1 (0.51) | HTTCACNA2D1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6026148 | 0.81 | CACNA2D1 (0.72) | HTTCACNA2D1GAAL3MBTL1ALDH1A1 | |
| SCHEMBL6081986 | 0.75 | HTT (0.52) | HTTCACNA2D1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6026147 | 0.73 | CACNA2D1 (0.56) | HTTCACNA2D1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7985622 | 0.71 | GAA (0.50) | HTTGAAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL6082444 | 0.71 | CACNA2D1 (0.55) | HTTCACNA2D1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL23779918 | 0.69 | CACNA2D1 (0.67) | CACNA2D1GAAALDH1A1KDM4EPOLB | |
| SCHEMBL6082653 | 0.69 | CACNA2D1 (0.59) | HTTCACNA2D1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6082602 | 0.69 | CACNA2D1 (0.59) | HTTCACNA2D1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6082187 | 0.69 | CACNA2D1 (0.54) | HTTCACNA2D1ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264420-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1539180-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1539180-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040048853-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004018058-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264420-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HTT 2077/4885CACNA2D1 3969/4885GAA 314/4885 |
| US-20040048853-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HTT 2077/4885CACNA2D1 3969/4885GAA 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.